Factors associated with hepatitis B vaccine series completion in a randomized trial for injection drug users reached through syringe exchange programs in three US cities

BMC Public Health

Volumn 14, Issue 1, 2014, Pages

  Bowman, Sarah ^a,b   Grau, Lauretta E ^a   Singer, Merrill ^c,d   Scott, Greg ^e   Heimer, Robert ^a  

^a YALE UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c HISPANIC HEALTH COUNCIL   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

^e DEPAUL UNIVERSITY   (United States)

Author keywords

Hepatitis B; Injection drug users; Syringe exchange programs; Vaccination

Indexed keywords

HEPATITIS B VACCINE;

ADOLESCENT; ADULT; AGE; AGED; CITY; COMPLICATION; CONTROLLED STUDY; DRUG USE; FEMALE; HEALTH STATUS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNIZATION; IMMUNOLOGY; MALE; MIDDLE AGED; ODDS RATIO; PREVENTIVE HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL; SUBSTANCE ABUSE; SYRINGE; UNITED STATES; VACCINATION; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CITIES; DRUG USERS; FEMALE; HEALTH STATUS; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNIZATION SCHEDULE; MALE; MIDDLE AGED; NEEDLE-EXCHANGE PROGRAMS; ODDS RATIO; SUBSTANCE ABUSE, INTRAVENOUS; SYRINGES; UNITED STATES; VACCINATION; YOUNG ADULT;

EID: 84908278410     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-14-820     Document Type: Article

References (51)

1. Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: Implications for vaccination programs. Goldstein ST, Alter MJ, Williams IT, Moyer LA, Judson FN, Mottram K, Fleenor M, Ryder PL, Margolis HS, J Infect Dis 2002 185 713 719
2. Surveillance for acute viral hepatitis - - United States, 2007. Daniels D, Grytdal S, Wasley A, MMWR Surveill Summ 2009 58 SS03 1 27
3. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE, Am J Publ Health 1996 86 655 661
4. Hepatitis B virus infection and immunization status in a new generation of injection drug users in San Francisco. Lum PJ, Hahn JA, Shafer KP, Evans JL, Davidson PJ, Stein E, Moss AR, J Viral Hepat 2008 15 229 236
5. Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus among injection drug users admitted to treatment in 6 US cities. Murrill CS, Weeks H, Castrucci BC, Weinstock HS, Bell BP, Spruill C, Gwinn M, Am J Publ Health 2002 92 395 398
6. Protection against viral hepatitis. Recommendations of the Immunization Practices Advisory Committee (ACIP). Anonymous, MMWR Recomm Rep 1990 39 RR-2 1 26
7. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, Rodewald LE, Douglas JMJ, Janssen RS, Ward JW, Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC), MMWR Recomm Rep 2006 55 RR-16 1 33
8. Accelerated hepatitis B vaccination schedule among drug users: a randomized controlled trial. Hwang L-Y, Grimes CZ, Tran TQ, Clark A, Xia R, Lai D, Triosi C, Williams M, J Infect Dis 2010 202 1500 1509
9. Providing hepatitis B vaccination to injection drug users: referral to health clinics versus on-site vaccination ar a syringe exchange program. Des Jarlais DC, Fisher DG, Newman JC, Trubatch BN, Yancovitz M, Paone D, Perlman D, Am J Publ Health 2001 91 1791 1792
10. A randomized controlled trial of monetary incentives vs outreach to enhance adherence to the hepatitis B vaccine series among injection drug users. Seal KH, Kral AH, Lorvick J, McNees A, Gee L, Edlin BR, Drug Alcohol Depen 2003 71 127 131
11. Hepatitis B virus infection and vaccination among young injection and non-injection drug users: missed opportunities to prevent infection. Kuo I, SS G, Thomas DL, Strathdee SA, Drug Alcohol Depen 2004 73 69 78
12. Convenience is the key to hepatitis A and B vaccination uptake among young adult injection drug users. Campbell JV, Garfein RS, Thiede H, Hagan H, Ouellet LJ, Golub ET, Hudson SM, Ompad DC, Weinbaum C, DUIT Study Team, Drug Alcohol Depen 2007 91 Suppl 1 64 S72
13. Vaccination against hepatitis B: Comparison of three different vaccination schedules. Jilg W, Schmidt M, Deinhardt F, J Infect Dis 1989 160 766 769
14. Comparison of a rapid hepatitis immunization schedule to the standard schedule for adults. Marsano LS, Greenberg RN, Kirkpatrick RB, Zetterman RK, Christiansen A, Smith DJ, DeMedina MD, Schiff ER, Am J Gastroenterol 1996 91 111 115
15. Evaluation of hepatitis B vaccination in injection drug users through syringe exchange programs. Hu Y, Grau LE, Scott G, Seal KH, Marshall PA, Singer M, Heimer R, Am J Prev Med 2008 35 25 32
16. Hepatitis B virus prevalence and vaccination rates among Hispanic injection drug users participating in a vaccination campaign operated at syringe exchange programs. Heimer R, Grau LE, Singer M, Scott G, Marshall PA, Hu Y, Seal KH, J Drug Issues 2008 38 335 350
17. Hepatitis-associated knowledge is low and risks are high among HIV-savvy injection drug users in three U.S cities. Heimer R, Clair S, Grau LE, Bluthenthal RN, Marshall PA, Singer S, Addiction 2002 97 1277 1287
18. Risk Behavior Assessment. National Institute on Drug Abuse, Book Risk Behavior Assessment North Bethesda, MD: NIDA 1991
19. Psychosocial and behavioral differences among drug injectors who use and do not use syringe exchange programs. Grau LE, Bluthenthal RN, Singer M, Marshall PA, Heimer R, AIDS Behav 2005 9 495 504
20. A protection motivation theory of fear appeals and attitude change. Rogers RW, J Psychol 1975 91 93 114
21. High rates of HIV infection among injection drug users participating in needle exchange programs in Montreal: results of a cohort study. Bruneau J, Lamothe F, Franco E, Lachance N, Desy M, Soto J, Vincelette J, Am J Epidemiol 1997 146 994 1002
22. Gender differences in syringe exchange program use in Oslo, Norway. Miller M, Eskild A, Mella I, Moi H, Magnus P, Addiction 2001 96 1639 1651
23. Vaccination strategies for targeted and difficult-to-access groups. Trubatch BN, Fisher DG, Cagle HH, Fenaughty AM, Am J Publ Health 2000 90 447
24. Compliance with hepatitis B vaccination in 1175 heroin users and risk factors associated with lack of vaccine response. Quaglio G, Talamini G, Lugoboni F, Lechi A, Venturini L, Des Jarlais DC, Mezzelani P, Addiction 2002 97 985 992
25. A review of the case for hepatitis B vaccination of high-risk adults. Rich JD, Ching CG, Lally MA, Gaitanis MM, Schwartzapfel B, Charuvastra A, Beckwith CG, Flanigan TP, Am J Med 2003 114 316 318
26. A 3-week hepatitis B vaccination schedule provides rapid and persistent protective immunity: a multicenter, randomized trial comparing accelerated and classic vaccination schedules. Marchou B, Excler JL, Bourderioux C, Salaun J, Picot N, Yvonnet B, Cerisier JE, Salomon H, Auvergnat JC, J Infect Dis 1995 172 258 260
27. Adherence to hepatitis B virus vaccination at syringe exchange sites. Altice FR, Bruce RD, Walton MR, Buitrago MI, J Urban Health 2005 82 151 161
28. An accelerated hepatitis B vaccination schedule for young drug users. Rogers N, Lubman DI, Australian & New Zealand J Public Health 2005 29 305 307
29. Feasibility of completing an accelerated vaccine series for homeless adults. Nyamathi AM, Sinha K, Saab S, Marfisee M, Greengold B, Leake B, Tyler D, J Viral Hepat 2009 16 666 673
30. A randomised controlled trial of financial incentives to increase hepatitis B vaccination completion among people who inject drugs in Australia. Topp L, Day CA, Wand H, Deacon RM, van Beek I, Haber PS, Shanahan M, Rodgers C, Maher L, Hepatitis Acceptability and Vaccine Incentives Trial (HAVIT) Study Group, Prev Med 2013 57 297 303
31. Use of contingency management incentives to improve completion of hepatitis B vaccination in people undergoing treatment for heroin dependence: a cluster randomised trial. Weaver T, Metrebian N, Hellier J, Pilling S, Charles V, Little N, Poovendran D, Mitchelson L, Ryan F, Bowden-Jones O, Dunn J, Glaspar A, Finch E, Strang J, Lancet 2014 384 153 163
32. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity, Lancet 2000 355 561 565
33. A review of the long-term protection after hepatitis A and B vaccination. Van Damme P, Van Herck K, Travel Med Infect Dis 2007 5 79 84
34. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. McMahon B, Dentinger CM, Bruden D, Zanis C, Peters H, Hurlburt D, Bulkow LF AE, Bell BP, Hennessy TW, J Infect Dis 2009 200 1390 1396
35. Hepatitis B vaccination in prisons: The Catalonian experience. Bayas JM, Bruguera M, Martin V, Vidal J, Rodes J, Salleras LY, Vaccine 1993 11 1441 1444
36. Methadone-maintained former heroin addicts, including those who are anti-HIV-1 seropositive, comply with and respond to hepatitis B vaccination. Borg L, Khuri E, Wells A, Melia D, Bergasa NV, Ho A, Kreek MJ, Addiction 1999 94 489 493
37. Mezzelani: Immunoresponse to hepatitis B vaccination and adherence campaign among injecting drug users. Lugoboni F, Magliozzi S, Schiesari F, Pauletto N, Bovo GL, Ciaffoni S, Vaccine 1997 15 1014 1016
38. Hepatitis B virus immunization among young injection drug users in San Francisco, Calif: the UFO Study. Lum PJ, Ochoa K, Hahn JA, Shafer KP, Evans JL, Moss AR, Amer J Publ Health 2003 93 919 923
39. Immune response to hepatitis B vaccine in parenteral drug abusers. Rodrigo JM, Serra MA, Aparisi L, Escudero A, Gilabert MS, Garcia F, Gonzalez R, del Olmo JA, Wassel AH, Artero A, Nogueira JM, Vaccine 1992 10 798 801
40. Response to hepatitis B vaccination in a primary care setting: influence of HIV infection, CD4+ lymphocyte count and vaccination schedule. Wong EK, Bodsworth NJ, Slade MA, Mulhall BP, Donovan B, Intl J STD AIDS 1996 7 490 494
41. A review of services and interventions for runaway and homeless youth: Moving forward. Slesnick N, Dashora P, Letcher A, Erdem G, Serovich J, Child Youth Serv Rev 2009 31 732 742
42. Investigation of a secondary syringe exchange program for homeless young adult injection drug users in San Francisco, California. Sears C, Guydish JR, Weltzien EK, Lum PJ, USA J AIDS 2001 27 193 201
43. Competing priorities as a barrier to medical care among homeless adults in Los Angeles. Gelberg L, Gallagher TC, Andersen RM PK, Am J Public Health 1997 87 217 220
44. Referral keeping in homeless women. Schlossstein E, St Clair P, Connell F, J Community Health 1991 16 279 285
45. Need for medical and psychosocial services among injection drug users: a comparative study of needle exchange and methadone maintenance. Stein MD, Friedmann PD, AM J Addiction 2002 11 262 270
46. Tuberculosis screening at a syringe exchange program. Perlman DC, Perkins MP, Solomon N, Kochems L, Des Jarlais DC, Paone D, Am J Publ Health 1997 87 862 863
47. Expanding harm reduction services through a wound and abscess clinic. Grau LE, Arevalo S, Catchpool C, Heimer R, Am J Publ Health 2002 92 1915 1917
48. Harnessing peer networks as an instrument for AIDS prevention: results from a peer-driven intervention. Broadhead RS, Heckathorn DD, Weakliem DL, Anthony DL, Madray H, Mills RJ, Hughes J, Public Health Rep 1998 113 Suppl 1 42 57
49. Increasing drug users' adherence to HIV treatment: results of a peer-driven intervention feasibility study. Broadhead RS, Heckathorn DD, Altice FL, van Hulst Y, Carbone M, Friedland GH, O'Connor PG, Selwyn PA, Soc Sci Med 2002 55 235 246
50. Peer-driven HIV interventions for drug injectors in Russia: First year impact results of a field experiment. Broadhead RS, Volkanevsky VL, Rydanova T, Ryabkova M, Borch C, van Hulst Y, Fullerton A, Sergeyev B, Heckathorn DD, Int J Drug Policy 2006 17 379 392
51. Rejuvenating harm reduction projects for injection drug users: Ukraine's nationwide introduction of peer-driven interventions. Smyrnov P, Broadhead RS, Datsenko O, Matiyash O, Int J Drug Policy 2012 23 141 147